Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Risk-adapted Therapy for AL Amyloidosis

NCT01527032 is registered in ClinicalTrials.gov with FDA Office of Orphan Products Development as lead sponsor.

NCT NCT01527032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01527032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Risk-adapted Therapy for AL Amyloidosis
Lead sponsor
FDA Office of Orphan Products Development
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2002
Completion date
September 30, 2005
Enrollment
Not reported
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

amyloidosis